The IBN SINA Pharmaceutical Industry PLC announcements
340 Dhaka Stock Exchange announcements for The IBN SINA Pharmaceutical Industry PLC (IBNSINA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (17).
- Credit Rating Result
Alpha Credit Rating PLC. has assigned Surveillance rating of the Company as "AA+" in the long term and "ST-1" in the short term along with Stable outlook based on audited financial statements up to 30 June, 2025 and relevant qualitative information till December 02, 2025.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 7.08 for July-September 2025 as against Tk. 2.72 for July-September 2024. Consolidated NOCFPS was Tk. 5.46 for July-September 2025 as against Tk. 9.71 for July-September 2024. Consolidated NAV per share was Tk. 132.67 as on September 30, 2025 and Tk. 125.69 as on June 30, 2025.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 11, 2025 at 2:45 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Resumption after Record Date
Trading of the shares of the company will resume on 27.10.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 26.10.2025.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 22.10.2025 to 23.10.2025 and trading of the shares will remain suspended on record date i.e., 26.10.2025.
- Dividend Declaration
The Board of Directors has recommended 64% Cash Dividend for the year ended June 30, 2025. Date of AGM: 23.11.2025, Time: 9:30 AM, Venue: Digital Platform. Record Date: 26.10.2025. The Company has also reported consolidated EPS of Tk. 20.27, consolidated NAV per share of Tk. 125.69 and consolidated NOCFPS of Tk. 23.16 for the year ended June 30, 2025 as against Tk. 21.46, Tk. 96.68 and Tk. 12.48 respectively for the year ended June 30, 2024.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (05.10.2025) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on September 30, 2025 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
- Board of Directors approval for Land Purchase in Feni District
The company has informed that the Board of Directors in its meeting held on June 29, 2025 has approved the Land Purchase in Feni District. To view the details, please visit: https://www.dsebd.org/Annexure/2025/IBN-SINA-Pharmaceutical-Industry-PLC-PSI2025.pdf
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 5.55 for January-March 2025 as against Tk. 4.31 for January-March 2024; Consolidated EPS was Tk. 15.02 for July 2024-March 2025 as against Tk. 16.32 for July 2023-March 2024. Consolidated NOCFPS was Tk. 26.16 for July 2024-March 2025 as against Tk. 15.50 for July 2023-March 2024. Consolidated NAV per share was Tk. 120.55 as on March 31, 2025 and Tk. 111.94 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2025 at 2:45 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 6.75 for October-December 2024 as against Tk. 6.70 for October-December 2023; Consolidated EPS was Tk. 9.47 for July-December 2024 as against Tk. 11.92 for July-December 2023. Consolidated NOCFPS was Tk. 17.25 for July-December 2024 as against Tk. 11.05 for July-December 2023. Consolidated NAV per share was Tk. 115.01 as on December 31, 2024 and Tk. 111.94 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 25, 2025 at 4:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
- Buy confirmation of Nominated Director
A. K. M. Sadrul Islam, Nominated Director of the Company, has further informed that he has completed his buying of 515 shares of the company at prevailing market price through Dhaka Stock Exchange as per declaration disseminated on 09.01.2025.
- Buy Declaration of Nominated Director
A. K. M. Sadrul Islam, Nominated Director of the Company, has expressed his intention to buy 515 shares of the Company at prevailing market price (in the Public Market) through Dhaka Stock Exchange PLC. within next 30 working days.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.